NCT/DKFZ MASTER handbook of interpreting whole-genome, transcriptome, and methylome data for precision oncology
-
Published:2023-10-26
Issue:1
Volume:7
Page:
-
ISSN:2397-768X
-
Container-title:npj Precision Oncology
-
language:en
-
Short-container-title:npj Precis. Onc.
Author:
Mock AndreasORCID, Teleanu Maria-Veronica, Kreutzfeldt Simon, Heilig Christoph E.ORCID, Hüllein Jennifer, Möhrmann LinoORCID, Jahn Arne, Hanf Dorothea, Kerle Irina A., Singh Hans MartinORCID, Hutter Barbara, Uhrig Sebastian, Fröhlich Martina, Neumann OlafORCID, Hartig Andreas, Brückmann Sascha, Hirsch SteffenORCID, Grund Kerstin, Dikow Nicola, Lipka Daniel B.ORCID, Renner Marcus, Bhatti Irfan Ahmed, Apostolidis Leonidas, Schlenk Richard F., Schaaf Christian P., Stenzinger AlbrechtORCID, Schröck EvelinORCID, Hübschmann DanielORCID, Heining Christoph, Horak PeterORCID, Glimm Hanno, Fröhling StefanORCID
Abstract
AbstractAnalysis of selected cancer genes has become an important tool in precision oncology but cannot fully capture the molecular features and, most importantly, vulnerabilities of individual tumors. Observational and interventional studies have shown that decision-making based on comprehensive molecular characterization adds significant clinical value. However, the complexity and heterogeneity of the resulting data are major challenges for disciplines involved in interpretation and recommendations for individualized care, and limited information exists on how to approach multilayered tumor profiles in clinical routine. We report our experience with the practical use of data from whole-genome or exome and RNA sequencing and DNA methylation profiling within the MASTER (Molecularly Aided Stratification for Tumor Eradication Research) program of the National Center for Tumor Diseases (NCT) Heidelberg and Dresden and the German Cancer Research Center (DKFZ). We cover all relevant steps of an end-to-end precision oncology workflow, from sample collection, molecular analysis, and variant prioritization to assigning treatment recommendations and discussion in the molecular tumor board. To provide insight into our approach to multidimensional tumor profiles and guidance on interpreting their biological impact and diagnostic and therapeutic implications, we present case studies from the NCT/DKFZ molecular tumor board that illustrate our daily practice. This manual is intended to be useful for physicians, biologists, and bioinformaticians involved in the clinical interpretation of genome-wide molecular information.
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Reference79 articles.
1. Malone, E. R., Oliva, M., Sabatini, P. J. B., Stockley, T. L. & Siu, L. L. Molecular profiling for precision cancer therapies. Genome Med. 12, 8 (2020). 2. Le Tourneau, C., Borcoman, E. & Kamal, M. Molecular profiling in precision medicine oncology. Nat. Med. 25, 711–712 (2019). 3. Shaw, K. R. M. & Maitra, A. The status and impact of clinical tumor genome sequencing. Annu. Rev. Genomics Hum. Genet. 20, 413–432 (2019). 4. Huang, K.-L. et al. Pathogenic germline variants in 10,389 Adult Cancers. Cell 173, 355–370.e14 (2018). 5. Luchini, C., Lawlor, R. T., Milella, M. & Scarpa, A. Molecular tumor boards in clinical practice. Trends Cancer Res. 6, 738–744 (2020).
|
|